NASDAQ:LPTX - Leap Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Leap Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $2.37 -0.20 (-7.78 %) (As of 02/25/2020 04:00 PM ET) Add Compare Today's Range$2.37Now: $2.37▼$2.6850-Day Range$1.58MA: $1.97▼$2.9052-Week Range$0.57Now: $2.37▼$3.18Volume813,831 shsAverage Volume1.25 million shsMarket Capitalization$57.34 millionP/E RatioN/ADividend YieldN/ABeta2.22 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in Phase I/II clinical trial in patients with esophagogastric, biliary tract, gynecologic, and non-small cell lung cancers, as well as hepatocellular carcinoma, a type of liver cancer. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:LPTX Previous Symbol CUSIPN/A CIK1509745 Webhttp://www.leaptx.com/ Phone617-714-0360Debt Debt-to-Equity Ratio0.12 Current Ratio1.39 Quick Ratio1.39Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.62 per share Price / Book3.82Profitability EPS (Most Recent Fiscal Year)($2.51) Net Income$-23,140,000.00 Net MarginsN/A Return on Equity-300.58% Return on Assets-161.73%Miscellaneous Employees23 Outstanding Shares24,195,000Market Cap$57.34 million Next Earnings Date4/6/2020 (Estimated) OptionableNot Optionable Receive LPTX News and Ratings via Email Sign-up to receive the latest news and ratings for LPTX and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:LPTX Rates by TradingView Leap Therapeutics (NASDAQ:LPTX) Frequently Asked Questions What is Leap Therapeutics' stock symbol? Leap Therapeutics trades on the NASDAQ under the ticker symbol "LPTX." How were Leap Therapeutics' earnings last quarter? Leap Therapeutics Inc (NASDAQ:LPTX) posted its earnings results on Thursday, November, 14th. The company reported ($0.33) EPS for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.33). View Leap Therapeutics' Earnings History. When is Leap Therapeutics' next earnings date? Leap Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, April 6th 2020. View Earnings Estimates for Leap Therapeutics. What price target have analysts set for LPTX? 3 brokers have issued 12-month price objectives for Leap Therapeutics' stock. Their forecasts range from $2.50 to $6.00. On average, they expect Leap Therapeutics' share price to reach $3.92 in the next twelve months. This suggests a possible upside of 65.3% from the stock's current price. View Analyst Price Targets for Leap Therapeutics. What is the consensus analysts' recommendation for Leap Therapeutics? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Leap Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Leap Therapeutics. Has Leap Therapeutics been receiving favorable news coverage? News stories about LPTX stock have been trending very negative recently, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Leap Therapeutics earned a coverage optimism score of -3.0 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for Leap Therapeutics. Are investors shorting Leap Therapeutics? Leap Therapeutics saw a increase in short interest in January. As of January 31st, there was short interest totalling 1,160,000 shares, an increase of 23.1% from the January 15th total of 942,100 shares. Based on an average trading volume of 656,900 shares, the days-to-cover ratio is currently 1.8 days. Approximately 8.0% of the company's stock are short sold. View Leap Therapeutics' Current Options Chain. Who are some of Leap Therapeutics' key competitors? Some companies that are related to Leap Therapeutics include Ocular Therapeutix (OCUL), BIOFRONTERA AG/ADR (BFRA), Protagonist Therapeutics (PTGX), Kalvista Pharmaceuticals (KALV), IVERIC bio (ISEE), MEI Pharma (MEIP), Geron (GERN), Kala Pharmaceuticals (KALA), VBI Vaccines (VBIV), XOMA (XOMA), Sol Gel Technologies (SLGL), MediciNova (MNOV), Agile Therapeutics (AGRX), Aeglea Bio Therapeutics (AGLE) and Theratechnologies (THERF). What other stocks do shareholders of Leap Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Leap Therapeutics investors own include Agile Therapeutics (AGRX), Nabriva Therapeutics (NBRV), Sorrento Therapeutics (SRNE), Amarin (AMRN), Anavex Life Sciences (AVXL), Verastem (VSTM), Aduro BioTech (ADRO), Fortress Biotech (FBIO), Pieris Pharmaceuticals (PIRS) and Senseonics (SENS). Who are Leap Therapeutics' key executives? Leap Therapeutics' management team includes the folowing people: Dr. Christopher K. Mirabelli Ph.D., CEO, Pres & Chairman (Age 65)Mr. Douglas E. Onsi J.D., CFO, Gen. Counsel, Treasurer & Sec. (Age 50)Mr. Augustine J. Lawlor, Chief Operating Officer (Age 63) Who are Leap Therapeutics' major shareholders? Leap Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include FMR LLC (2.73%). View Institutional Ownership Trends for Leap Therapeutics. Which major investors are selling Leap Therapeutics stock? LPTX stock was sold by a variety of institutional investors in the last quarter, including FMR LLC. View Insider Buying and Selling for Leap Therapeutics. How do I buy shares of Leap Therapeutics? Shares of LPTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Leap Therapeutics' stock price today? One share of LPTX stock can currently be purchased for approximately $2.37. How big of a company is Leap Therapeutics? Leap Therapeutics has a market capitalization of $57.34 million. The company earns $-23,140,000.00 in net income (profit) each year or ($2.51) on an earnings per share basis. Leap Therapeutics employs 23 workers across the globe.View Additional Information About Leap Therapeutics. What is Leap Therapeutics' official website? The official website for Leap Therapeutics is http://www.leaptx.com/. How can I contact Leap Therapeutics? Leap Therapeutics' mailing address is 47 THORNDIKE STREET SUITE B1-1, CAMBRIDGE MA, 02141. The company can be reached via phone at 617-714-0360. MarketBeat Community Rating for Leap Therapeutics (NASDAQ LPTX)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 232 (Vote Outperform)Underperform Votes: 219 (Vote Underperform)Total Votes: 451MarketBeat's community ratings are surveys of what our community members think about Leap Therapeutics and other stocks. Vote "Outperform" if you believe LPTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LPTX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/25/2020 by MarketBeat.com StaffFeatured Article: Does a trade war provide a risk to the global economy?
